Insulet Q2 FY26: where the revenue came from and where it went
The whole income statement of Insulet for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2026
- Reported
- Aug 5, 2026
Revenue$0.80B
+24% year over year
Gross profit$0.56B
70% margin
Operating profit$0.13B
16% margin
Net profit$0.10B
12% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.80 | 100% | +24% |
| U.S. | 0.52 | 64% | |
| International | 0.24 | 30% | |
| Other | 0.04 | 5% | |
| Drug delivery | <0.01 | 1% | |
| Cost of revenue | −0.24 | 30% | |
| Gross profit | 0.56 | 70% margin | +1pp |
| R&D | −0.09 | 11% | +0pp |
| SG&A | −0.35 | 43% | +3pp |
| Operating profit | 0.13 | 16% margin | −2pp |
| Interest & other costs | −0.01 | ||
| Tax | −0.02 | ||
| Net profit | 0.10 | 12% margin | +8pp |
129 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest